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espite the devastating impact that mood disor-
ders have on the lives of millions worldwide,there is still a
dearth of knowledge concerning their underlying etiology
and pathophysiology.The brain systems that have hereto-
fore received the greatest attention in neurobiological
studies of mood disorders have been the monoaminergic
neurotransmitter systems,which are extensively distrib-
uted throughout the network of limbic,striatal,and pre-
frontal cortical neuronal circuits thought to support the
behavioral and visceral manifestations of mood disor-
ders.
1-3 Thus, clinical studies over the past 40 years have
attempted to uncover the specific defects in these neuro-
transmitter systems in mood disorders by utilizing a vari-
ety of biochemical and neuroendocrine strategies.
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There is increasing evidence from a variety of sources that severe mood disorders are associated with regional reduc-
tions in brain volume, as well as reductions in the number, size, and density of glia and neurons in discrete brain areas.
Although the precise pathophysiology underlying these morphometric changes remains to be fully elucidated, the
data suggest that severe mood disorders are associated with impairments of structural plasticity and cellular resilience.
In this context, it is noteworthy that a growing body of data suggests that the glutamatergic system (which is known
to play a major role in neuronal plasticity and cellular resilience) may be involved in the pathophysiology and treat-
ment of mood disorders. Glutamate  -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) GluR1 receptor
trafficking plays a critical role in regulating various forms of neural plasticity. It is thus noteworthy that recent studies
have shown that structurally dissimilar mood stabilizers lithium and valproate regulate GluR1 receptor subunit traf-
ficking and localization at synapses. These studies suggest that regulation of glutamatergically mediated synaptic plas-
ticity may play a role in the treatment of mood disorders, and raises the possibility that agents more directly affect-
ing synaptic GluR1 represent novel therapies for these devastating illnesses. 
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(e-mail: manjih@intra.nimh.nih.gov)While such investigations have been heuristic over the
years,they have been of limited value in elucidating the
unique biology of mood disorders, which must include
an understanding of the underlying basis for the
predilection to episodic and often-profound mood dis-
turbance, which can become progressive over time.
These observations have led to the appreciation that,
while dysfunction within the monoaminergic neuro-
transmitter systems is likely to play important roles in
mediating some components of the pathophysiology of
mood disorders, they do not fully explain all the facets
of these complex neuropsychiatric disorders.
4,5
In addition to the acknowledgement that investigations
into the pathophysiology of complex mood disorders have
been excessively focused on monoaminergic systems,there
has been a growing appreciation that progress in devel-
oping truly novel and improved medications has conse-
quently also been limited.A recognition of the clear need
for better treatments and the lack of significant advances
in our ability to develop novel,improved therapeutics for
these devastating illnesses has led to the investigation of
the putative roles of intracellular signaling cascades and
nonaminergic systems in the pathophysiology and treat-
ment of mood disorders.Consequently,recent evidence
demonstrating that impairments of neuroplasticity may
underlie the pathophysiology of mood disorders,and that
antidepressants and mood stabilizers exert major effects
on the signaling pathways that regulate cellular plasticity
and resilience,have generated considerable excitement
among the clinical neuroscience community, and are
reshaping views about the neurobiological underpinnings
of these disorders.
1,2,6-8
Somewhat surprisingly, the potential role of the gluta-
matergic system in the pathophysiology and treatment
of bipolar disorder has only recently begun to be inves-
tigated in earnest. Glutamate is the major excitatory
synaptic neurotransmitter regulating numerous physi-
ological functions in the mammalian central nervous sys-
tem (CNS), such as synaptic plasticity, learning, and
memory, and represents a major neurotransmitter sys-
tem in the circuitry thought to subserve many of the
symptoms of severe, recurrent mood disorders.
3 In this
perspectives paper,we review the growing body of data
that suggests that severe mood disorders are associated
with impairments of cellular plasticity and resilience,
effects that may arise from perturbations of neu-
rotrophic signaling cascades and the glutamatergic sys-
tem.We follow with a discussion of the emerging data
that suggests regulating the balance of glutamatergic
throughput via N-methyl-D-aspartate (NMDA) and 
α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid
(AMPA) receptors may play an important role in the
actions of our most effective thymoleptic agents, and
represent very attractive targets for the development of
novel therapeutics for these devastating disorders.
What is the evidence for impairments of 
cellular plasticity and resilience in 
severe mood disorders?
Structural imaging studies have demonstrated reduced
gray matter volumes in areas of the orbital and medial
prefrontal cortex (PFC), ventral striatum, and hip-
pocampus,and enlargement of third ventricle in mood-
disordered patients relative to healthy control sam-
ples.
3,9,10 Postmortem neuropathological studies have
shown abnormal reductions in glial cell counts/density,
neuron size/density,and cortical volume/thickness in the
subgenual PFC,orbital cortex,dorsal anterolateral PFC,
amygdala,and in basal ganglia and dorsal raphe nuclei
and hippocampus.
11-16 Morphometric studies also have
reported layer-specific reductions in interneurons in the
anterior cingulate cortex (ACC),and reductions in non-
pyramidal neurons (~40% lower) in CA2 of the hip-
pocampal formation in bipolar disorder subjects com-
pared with controls.
17 Overall,the layer-specific cellular
changes observed in several distinct brain regions,includ-
ing the PFC,ACC,and hippocampus suggest that multi-
ple neuronal circuits underlie the neuropathology of
mood disorders.This is not altogether surprising since the
behavioral and physiological manifestations of the ill-
nesses are complex and include cognitive, affective,
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Selected abbreviations and acronyms
AMPA  -amino-3-hydroxy-5-methyl-4-isoxazole propi-
onic acid
CAMKII calcium/calmodulin-dependent protein kinase II
EAAT excitatory amino acid transporter
LTD long-term depression
LTP long-term potentiation
NMDA N-methyl-D-aspartate
MAPK mitogen-activated protein kinase
PCP phencyclidine
PKA protein kinase A
PP1 protein phosphatase 1
WMH white matter hyperintensitiesmotoric,and neurovegetative symptomatology,as well as
alterations of circadian rhythms and neuroendocrine sys-
tems,and are thus undoubtedly mediated by networks of
interconnected neurotransmitter systems and neural cir-
cuits.
13 In addition to the accumulating neuroimaging evi-
dence, several postmortem brain studies are now pro-
viding direct evidence for reductions in regional CNS
volume, cell number, and cell body size. Baumann and
associates
18 reported reduced volumes of the left nucleus
accumbens, the right putamen, and bilateral pallidum
externum in postmortem brain samples obtained from
patients with unipolar depression or bipolar depression.
The abnormal presence of white matter hyperintensities
(WMH) has been reported in multiple magnetic reso-
nance imaging (MRI) studies of geriatric patients with
affective disorder, particularly those with late-onset
depression (ie, elderly depressed patients who experi-
ence their first depression after age 60). Elderly adults
(>60 years old) with severe WMH are 3 to 5 times more
likely to have depressive symptoms as compared with
persons with only mild or no white matter lesions.
19
Tupler and colleagues
20 reported that late-onset
depressed patients had more severe hyperintensity rat-
ings in deep white matter than early-onset patients and
controls, and that late- and early-onset patients had
more severe subcortical gray matter hyperintensities
(particularly in the putamen) compared with controls.
Recently, Silverstone and colleagues
21 reported that
bipolar patients showed more severe deep WMH on
brain MRI than age-matched unipolar and control sub-
jects. WMH severity has been suggested to predict
poorer response to antidepressant therapy.
22 In fact,
these lesions have been also found to be increased in
children with psychiatric disorders, but are highest
among bipolar patients, when compared with controls,
particularly in the frontal lobes,
23 and also early in the
course of bipolar illness in adolescent subjects.
24
Although the cause of WMH in mood disorders is
unknown, their presence—particularly in the brains of
young bipolar patients—suggests importance in the
pathophysiology of the disorder.
25,26 Together, these
results support the contention that WMH indicate dam-
age to the structure of brain tissue,and likely disruption
of the neuronal connectivity necessary for normal affec-
tive functioning.
It is not known whether these structural brain changes
seen in patients with severe mood disorders constitute
developmental abnormalities that may confer vulnerabil-
ity to abnormal mood episodes,compensatory changes to
other pathogenic processes,or the sequelae of recurrent
affective episodes per se.Understanding these issues will
partly depend upon experiments that delineate the onset
of such abnormalities within the illness course and deter-
mine whether they antedate depressive episodes in indi-
viduals at high familial risk for mood disorders.Neverthe-
less,these prominent atrophic changes and impairments
of plasticity have drawn much attention to the gluta-
matergic system,since—as we discuss in detail below—the
glutamatergic system is known to play critical roles in reg-
ulating various forms of plasticity.Furthermore,as is dis-
cussed extensively in this issue and elsewhere,
27 alterations
in glutamatergic signaling,mediated by both NMDA and
non-NMDA receptors,are known to play important roles
in stress-induced morphometric brain changes.
14,28,29 Since
some clinicians may be less familiar with the intricacies of
the regulation of glutamate receptor subtypes,we now pre-
sent a brief overview of the functioning and regulation of
NMDA and AMPA glutamatergic receptors.We follow
with a discussion of the exciting emerging data suggesting
that glutamatergic signaling represents a very attractive
target for the development of novel therapeutics for
severe mood disorders.
A primer on glutamatergic signaling: 
critical roles in cellular plasticity 
and resilience
As the principal mediator of excitatory synaptic transmis-
sion in the mammalian brain, glutamate participates in
wide-ranging aspects of both normal and abnormal CNS
function.Unlike the monoamines,which require transport
of amino acids through the blood–brain barrier,glutamate
and aspartate cannot adequately penetrate into the brain
from the periphery and are produced locally by special-
ized brain machinery.
30 The metabolic and synthetic
enzymes responsible for the formation of these nonessen-
tial amino acids are located in glial cells as well as neu-
rons.
30,31The major metabolic pathway in the production of
glutamate is derived from glucose and the transamination
of α-ketoglutarate;however,a small proportion of gluta-
mate is formed directly from glutamine.The latter is actu-
ally synthesized in glia, via an active process (requiring
adenosine triphosphate [ATP]),and is then transported to
neurons where glutaminase is able to convert this precur-
sor to glutamate (Figure 1). Following release, the con-
centration of glutamate in the extracellular space is highly
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Figure 1. Glutamatergic system. This figure depicts the various regulatory processes involved in glutamatergic neurotransmission, as described in
the text. In astrocytes, glutamine can undergo oxidation to yield α-ketoglutarate, which can also be transported to neurons and participate
in glutamate synthesis. Glutamate is either metabolized or sequestered and stored into secretory vesicles by vesicular glutamate transporters
(VGluT). Glutamate can then be released by a calcium-dependent excitotoxic process. Glutamate has its action terminated in the synapse
by reuptake mechanisms utilizing distinct GLU transporters (GLUTs), which exist not only on presynaptic nerve terminals, but also on astro-
cytes; indeed, current data suggests that astrocytic glutamate uptake may be more important for clearing excess glutamate, raising the pos-
sibility that astrocytic loss (as has been documented in mood disorders) may contribute to deleterious GLU signaling, but more so by astro-
cytes. It is now known that there are a number of important intracellular proteins, which are able to alter the function of glutamate receptors.
Gly, glycine; GTn, glutamate transporter; GTg, glutamate transporter (glial); 5-HT1A, 5-hydroxytryptamine (serotonin) receptor 1A; AMPA,
α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid; NMDAR, NMDA receptor; PKA and PKC, protein kinase A and C; PP1, PP2A, and
PP2B, protein phosphatase 1, 2A, and 2B; Yotiao, NMDA receptor accessory protein; AKAP, protein A kinase anchoring protein; nNOS, nitric
oxide synthetase; Src, a family of protein tyrosine kinases; PTP1D, protein-tyrosine phosphatase 1D; SHP2, src homology 2 domain–contain-
ing tyrosine phosphatase; PSD95, postsynaptic density protein 95; CAMKII, calcium/calmodulin-dependent protein kinase II; MyoV, myosin V;
SynGAP, Ras guanosine triphosphatase (GTPase)–activating protein; GKAP, guanylate kinase–associated protein; PYK2, proline-rich tyrosine
kinase-2; Shank; Shank family of multidomain proteins; Homer, a family of dendritic multidomain proteins; Rap2, a small GTPase; H-ras,
Harvey rat sarcoma viral oncogene homologue; Rac1, a Rho family GTPase; ERK, extracellular signal–regulated kinase; Raf, MEK, and Rsk,
ribosomal S6 kinases; Hsp70, heat-shock protein 70.
Modified and reproduced with permission from reference 30: Szabo ST, Gould TD, Manji HK. Neurotransmitters, receptors, signal transduction, and second
messengers in psychiatric disorders. In: Schatzberg A, Nemeroff CB, eds. The American Psychiatric Publishing Textbook of Psychopharmacology. Arlington,
VA: American Psychiatric Publishing Inc; 2003:3-52. Copyright © 2003; American Psychiatric Publishing Inc.regulated and controlled,primarily by a sodium-depen-
dent reuptake mechanism involving several transporter
proteins.The major glutamate transporter proteins found
in the CNS include excitatory amino acid transporters
(EAATs):EAAT1 (or GLAST-1),EAAT2 (or GLT-1),
and EAAT3 (or EAAC1), with EAAT2 being the 
most predominantly expressed form in the forebrain.
Additionally,these transporters are differentially expressed
in specific cell types, with EAAT1 and EAAT2 being
found primarily in glial cells,EAAT3 localized in neurons,
and EAAT4 mainly localized in cerebellum.The physio-
logical events regulating the activity of the glutamate
transporters are not well understood,though there is evi-
dence that phosphorylation of the transporters by protein
kinases may differentially regulate glutamate transporters
and therefore glutamate reuptake (discussed in reference
30).Glutamate concentrations have been shown to rise to
excitotoxic levels within minutes following traumatic or
ischemic injury,and there is evidence that the function of
the glutamate transporters becomes impaired under these
excitotoxic conditions.
32 Moreover,microdialysis studies
have shown that severe stress increases extracellular lev-
els of glutamate in hippocampus,and NMDA glutamate
receptor antagonists attenuate stress-induced atrophy of
CA3 pyramidal neurons.
Glutamate receptor subtypes: a focus on NMDA and
AMPA receptors
The many subtypes of glutamatergic receptors in the CNS
can be classified into two major subtypes—the ionotropic
and metabotropic receptors (Table I).The ionotropic glu-
tamate receptor ion channels are assemblies of homo-
oligomeric or hetero-oligomeric subunits integrated into
the neuron’s membrane. Every channel is assembled of
(most likely) four subunits associated into a dimer of
dimers,as has been observed in crystallographic studies.
33,34
Every subunit consists of an extracellular amino terminal
and ligand-binding domain,three transmembrane domains
and a re-entrant pore loop (located between the first and
second transmembrane domains),and an intracellular car-
boxyl terminal domain.
35The subunits associate through
interactions between their amino terminal domains form-
ing a dimer that undergoes a second dimerization medi-
ated by interactions between the ligand-binding domains
and/or between transmembrane domains.
33,34Three differ-
ent subgroups of glutamatergic ion channels have been
identified utilizing their pharmacological ability to bind dif-
ferent synthetic ligands,each of which is composed of a dif-
ferent set of subunits. These are the NMDA receptor
(NMDAR), the AMPA receptor (AMPAR), and the
kainate receptor (KAR).The latter two groups are often
referred to together as the “non-NMDA” receptors, but
undoubtedly subserve unique functions (Table I).In the
adult mammalian brain,NMDA and AMPA glutamater-
gic receptors are colocalized in approximately 70% of the
synapses.
36 By contrast, at early stages of development,
synapses are more likely to contain only NMDA receptors.
Radioligand binding studies have shown that NMDA and
AMPA receptors are found in high density in the cerebral
cortex,hippocampus,striatum,septum,and amygdala.
NMDA receptors
The NMDA receptor is activated by glutamate and
requires the presence of a coagonist,namely glycine or 
D-serine,to be activated.However,the binding of both
glutamate and glycine is still not sufficient for the NMDA
receptor channel to open, since, at resting membrane
potential,the NMDA ion channel is blocked by Mg
2+ ions.
Only when the membrane is depolarized (eg,by the acti-
vation of AMPA or kainate receptors on the same post-
synaptic neuron) is the Mg
2+ blockade relieved. Under
these conditions,the NMDA receptor channel will open
and permit the entry of both Na
+ and Ca
2+ (Figure 1).
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Table I. Receptor subtype units. Once released from the presynaptic ter-
minal, glutamate is able to bind to numerous excitatory amino
acid (EAA) receptors, including both ionotropic (eg, N-methyl-D-
aspartate [NMDA]) and metabotropic receptors. Presynaptic reg-
ulation of glutamate release occurs through metabotropic glu-
tamate receptors (mGluR2 or mGluR3), which subserve the
function of autoreceptors. However, these receptors are also
located on the postsynaptic element. AMPA, α-amino-3-hydroxy-
5-methyl-4-isoxazole propionic acid.
Ionotropic receptors
NMDA • NR1
• NR2A, NR2B, NR2C, NR2D
• NR3A, NR3B
AMPA • GluR1, GluR2, GluR3, GluR4
Kainate • GluR5, GluR6, GluR7
• KA1, KA2
Metabotropic receptors
Group I • mGlu1a, mGlu1b, mGlu1c, mGlu1d
Group II • mGlu2, mGlu3
Group III • mGlu4a, mGlu4b, mGlu4c, mGlu4d
• mGlu6
• mGlu7a, mGlu7b, mGlu7c, mGlu7d
• mGlu8a, mGlu8b, mGlu8c, mGlu8dThe NMDA receptor channel is composed of combina-
tion of NR1, NR2A, NR2B, NR2C, NR2D, NR3A, and
NR3B subunits (Table I).The binding site for glutamate
has been localized to the NR2 subunit and the site for
the coagonist glycine has been localized to the NR1 sub-
unit, which is required for receptor function.Two mol-
ecules of glutamate and two of glycine are thought to be
necessary to activate the ion channel. Within the ion
channel, two other sites have been identified called the
sigma (σ) site and the phencyclidine (PCP) site.The hal-
lucinogenic drug PCP, ketamine, and the experimental
drug dizocilpine (MK-801),all bind at the latter site and
are considered noncompetitive receptor antagonists that
inhibit NMDA receptor channel function.In preclinical
studies,drugs of this type have been shown to have neu-
roprotective properties against anoxia and hypo-
glycemia; these studies await clinical confirmation. In
clinical psychiatric studies,ketamine has been shown to
transiently induce psychotic symptoms in schizophrenic
patients, and to produce rapid antidepressant effects in
depressed patients.
37 These latter observations have led
to the investigation of NMDA antagonists as putative
novel antidepressants.
29,37
NMDA receptors play a critical role in regulating synap-
tic plasticity.
38The best-studied forms of synaptic plasticity
in the CNS are long-term potentiation (LTP) and long-
term depression (LTD) of excitatory synaptic transmis-
sion.The molecular mechanisms of LTP and LTD have
been extensively characterized and have been proposed
to represent cellular models of learning and memory.
38
Induction of LTP and LTD in the CA1 region of the hip-
pocampus and in many regions of the brain has now
clearly been demonstrated to be dependent on NMDA
receptor activation.During NMDA-receptor–dependent
synaptic plasticity,Ca
2+ influx through NMDA receptors
can activate a wide variety of kinases and/or phosphatases
that, in turn, modulate synaptic strength.An important
recent development is the finding that two of the primary
molecules involved––Ca
2+/ calmodulin-dependent protein
kinase II (CAMKII) and the NMDA subtype of glutamate
receptor––form a tight complex with each other at the
synapse.
39 Interestingly,this binding appears to enhance
both the autophosphorylation of the kinase and the abil-
ity of the entire holoenzyme, which has 12 subunits, to
become hyperphosphorylated.
39This hyperphosphorylated
state has been postulated to represent a “memory switch,”
which can lead to long-term strengthening of the synapse
by multiple mechanisms. One important mechanism
involves direct phosphorylation of the glutamate-activated
AMPA receptors, which increases their conductance.
Furthermore, once CAMKII is bound to the NMDA
receptor, it may organize additional anchoring sites for
AMPA receptors at the synapse.
It is intriguing that activation of synaptic NMDA receptor
versus nonsynaptic receptor has an opposite effect on cell
survival via differential regulation of CREB (cyclic adeno-
sine monophosphate [cAMP]–response element binding
protein) function.Calcium entry through synaptic NMDA
receptors induced CREB activity and brain-derived neu-
rotrophic factor (BDNF) gene expression as strongly as
did stimulation of L-type calcium channels. In contrast,
calcium entry through nonsynaptic NMDA receptors,trig-
gered by glutamate exposure or hypoxic/ischemic condi-
tions, activated a general and dominant CREB shut-off
pathway that blocked induction of BDNF expression.
Synaptic NMDA receptors have antiapoptotic activity,
whereas stimulation of extrasynaptic NMDA receptors
caused loss of mitochondrial membrane potential (an early
marker for glutamate-induced neuronal damage) and cell
death.
40
AMPA receptor trafficking plays critical roles in the
regulation of various forms of neural plasticity
The AMPA receptor is stimulated by the presence of
glutamate and characteristically produces a fast excita-
tory synaptic signal that is responsible for the initial
reaction to glutamate in the synapse.In fact,as discussed
above,it is generally believed that it is the activation of
the AMPA receptor that results in neuronal depolariza-
tion sufficient to liberate the Mg
2+ cation from the
NMDA receptor, thereby permitting its activation.The
AMPA receptor channel is composed of the combina-
tion of GluR1,GluR2,GluR3,and GluR4 subunits,and
requires two molecules of glutamate to be activated
(Table I).AMPA receptors have a lower affinity for glu-
tamate than the NMDA receptor, thereby allowing for
more rapid dissociation of glutamate and therefore a
rapid deactivation of the AMPA receptor (reviewed in
reference 41).
Emerging data suggest that AMPA receptor trafficking,
including receptor insertion and internalization,and deliv-
ery to synaptic sites,provides an elegant mechanism for
activity-dependent regulation of synaptic strength.AMPA
receptor subunits undergo constitutive endocytosis and
exocytosis;however,the process is highly regulated with a
Basic research
148variety of signal transduction cascades being capable of
producing short- or long-term changes in synaptic surface
expression of AMPA receptor subunits.Indeed,although
the mechanisms of LTP and LTD have not been com-
pletely elucidated,it is widely accepted that AMPA recep-
tor trafficking is the key player in these phenomena.
Most importantly for the present discussion, AMPA
receptor trafficking is highly regulated by the protein
kinase A (PKA),protein kinase C (PKC),CAMKII,and
mitogen-activated protein kinase (MAPK) signaling cas-
cades; these are the very same signaling cascades that
mood stabilizers and antidepressants exert major effects
on.
42-45These observations have led to an extensive series
of studies,which have clearly demonstrated that AMPA
receptor trafficking is highly regulated by antidepres-
sants and mood stabilizers
46,47 (see below).
Regulation of AMPA receptor trafficking by signaling
cascades
Most vesicle trafficking requires the ordered coating of
a donor membrane, budding and fusion to form trans-
port vesicles, transport by passive or active delivery
along microtubule,and final fusion with the target mem-
brane.
48AMPA receptors adopted this mechanism to be
delivered to the neuronal membrane surface. AMPA
receptors are multimeric assemblies of the subunits
GluR1 to GluR4.Each subunit is composed of N-termi-
nal extracellular domain, membrane-spanning domain,
and C-terminal intracellular domain.
49,50AMPA receptor
trafficking is subunit-specific and regulated by phos-
phorylation of its C-terminal domain, and subsequent
alteration of protein-protein interactions.
PKA pathway 
The GluR1 subunit appears to govern the trafficking
behavior of heteromeric GluR1/GluR2 receptors, pre-
venting constitutive exchange and conferring inducible
delivery of the heteromer.
51 Phosphorylation of GluR1 at
the PKA site p845 facilitates the insertion of GluR1 onto
the membrane and synapses,and is often associated with
LTP.
52 Dephosphorylation of the GluR1 by protein phos-
phatases (eg, calcineurin and protein phosphatase 1
[PP1]) target GluR1 to recycling endosomes, where
rephosphorylation by PKA may occur and the receptors
will be reinserted onto the membrane.
53 Phosphorylation
of GluR1 at PKA site can be enhanced by synapse-asso-
ciated protein 97 (SAP97)/protein A kinase anchoring
protein (AKAP79) complex that direct PKA to GluR1
via a PDZ (PSD95,disk large,ZO1) domain interaction.
54
CAMKII pathway
Numerous studies have demonstrated that CAMKII is
required for the proper formation of LTP in slice prepa-
rations, and in regulating learning and memory in
rodents.
55 In response to stimulation, CAMKII translo-
cates to the postsynaptic site, where it has two major
effects on AMPA receptor activity at the postsynaptic
site during the formation of LTP.
55 First,the AMPA sin-
gle conductance is directly increased by CAMKII at
Ser831 of GluR1 subunit.
56 Second,CAMKII is required
for the delivery of AMPA receptor to the synapse,which
is lacking AMPA receptors.
51,57,58 This enhancement of
synaptic GluR1 level by activation of CAMKII requires
an intact C-terminal domain of GluR1, and is possibly
involved in interaction with SAP97.
59 PP1,which is also
known to be a important modulator for learning and
memory, can dephosphorylate the phosphorylation of
GluR1 at p831 site by CAMKII.
60
Extracellular signal–regulated kinase (ERK) MAPK
pathway
A recent study reported that the small guananine triphos-
phatases (GTPases) Ras and Rap are involved in AMPA
receptor trafficking through a postsynaptic signaling mech-
anism. Ras mediates activity-evoked increase in
GluR1/GluR4–containing AMPA receptor surface expres-
sion at synapses via a pathway that requires p42/44 MAPK
activation.In contrast,Rap mediates NMDA-dependent
removal of synaptic GluR2/GluR3–containing vesicles via
a pathway that involves p38 MAPK. The regulation
through Ras and Rap,which work as molecular switches,
may in turn control the AMPA receptor level at synapses.
61
PKC pathways
AMPA GluR2 receptors respond to secondary signals
by constitutive receptor recycling. Phosphorylation of
Ser880 on GluR2 provides a switch from receptor reten-
tion at the membrane by binding to ABP (AMPA recep-
tor–binding protein)/GRIP (glutamate receptor–inter-
acting protein),to receptor internalization by binding to
PICK 1 (protein interacting with C kinase-1).Therefore,
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release the AMPA receptor from the anchoring proteins
and initiate the internalization of receptors.
62-65
The mechanism for AMPA receptor trafficking is spe-
cific for brain region and neuronal type.For example,the
endocytosis of AMPA receptors mediating LTD is trig-
gered by very different signaling cascades in different
cell types despite the fact that a conserved cell biologi-
cal mechanism (ie, clathrin/dynamine-dependent endo-
cytosis) always seems to be involved.Specifically,in CA1
pyramidal cells, protein phosphatases seem to be
involved in triggering LTD through dephosphorylation
of GluR1 and phosphorylation of PKA site on GluR1 is
associated with LTP.
53 However, in midbrain dopamine
cells, activation of PKA appears to trigger LTD and
endocytosis of AMPA receptors.
66
AMPA receptor trafficking and mood 
disorders: implication for development
of new medications
In view of the critical role of AMPA receptor trafficking
in regulating various forms of plasticity, our laboratory
has sought to determine if two structurally highly dis-
similar antimanic agents, lithium and valproate, exert
effects on AMPA receptor trafficking.Lithium,a mono-
valent cation,and valproic acid (VPA),an 8-carbon fatty
acid, are the two most commonly used agents in the
treatment of mania.Because lithium and valproate both
require several weeks to exert their therapeutic effects,
it is widely believed that adaptive changes in intracellu-
lar signaling and/or cellular physiology underlie the ben-
eficial effects; interestingly, these two agents have been
shown to exert robust effects on the very same signaling
pathways known to regulate AMPA receptor trafficking
(vide supra).Thus,we investigated whether lithium and
valproate regulate synaptic plasticity and AMPA recep-
tor trafficking in the hippocampus, a brain region pre-
sumed to be involved in the circuitry of mood disorders.
3
We have found that the structurally highly dissimilar
antimanic agents lithium and valproate have a common
effect on downregulating AMPA GluR1 synaptic
expression in the hippocampus after prolonged treat-
ment with therapeutically relevant concentrations as
assessed both in vitro and in vivo. In cultured hip-
pocampal neurons,lithium and valproate attenuated sur-
face GluR1 expression after long-term treatment.
Further supporting the therapeutic relevance of the find-
ing,we found that an agent that provokes mania,namely
the antidepressant imipramine, has an opposite effect 
as it upregulates AMPA synaptic strength in the hip-
pocampus.
47,67
Since chronic administration of mood stabilizers bring
about numerous biochemical effects, our laboratory
8,68
and others
69 have established several criteria that find-
ings should meet in order to maximize the likelihood of
their therapeutic importance:
•This effect of mood stabilizers on GluR1 is a common
effect of the structurally dissimilar antimanic agents
lithium (a monovalent cation) and valproate (which is
an 8-carbon branched fatty acid).
•This attenuation of synaptic GluR1 by lithium and val-
proate occurs in the hippocampus,a brain region known
to be involved in critical affective neuronal circuits.
•This effect of lithium and valproate on synaptic GluR1
occurs at therapeutic concentrations both in vivo and
in vitro.
• Similar to the clinical therapeutic effects, the changes
in GluR1 were observed only after chronic (and not
acute) administration.
•The effects were specific for antimanic agents, as a
promanic antidepressant produced opposite effects.
While it is impossible to determine whether synaptic
GluR1 attenuation occurs in patients being treated
with lithium or valproate,our experimental conditions
attempt to mimic this situation as closely as possible.
Further supporting our data are recent studies that show
that AMPA receptor antagonists attenuate several
“manic-like” behaviors produced by amphetamine
administration. Thus, AMPA antagonists have been
demonstrated to attenuate psychostimulant-induced
development or expression of sensitization and hedonic
behavior without affecting spontaneous locomotion;
additionally, some studies have demonstrated that
AMPA receptor antagonists reduce amphetamine- or
cocaine-induced hyperactivity.
70-75 The need to use cau-
tion in the appropriate application of animal models to
complex neuropsychiatric disorders has been well artic-
ulated, and in fact it is unlikely we will ever develop
rodent models that display the full range of symptoma-
tology clinically expressed in man.
76,77 However,one cur-
rent model of mania, which has been extensively used
and has reasonable heuristic value in the study of mood
disorders,involves the use of psychostimulants in appro-
priate paradigms.Thus,psychostimulants like ampheta-
mine and cocaine are known to induce manic-like symp-
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150toms in healthy volunteers, and trigger frank manic
episodes in individuals with bipolar disorder.
78Thus,the
best-established animal models mania utilize the admin-
istration of amphetamine or cocaine to produce hyper-
activity, risk-taking behavior, and increased hedonic
drive—all very important facets of the human clinical
condition of mania. Moreover, these psychostimulant-
induced behavioral changes are attenuated by the
administration of chronic lithium in a therapeutically rel-
evant time frame.Thus, the fact that AMPA receptor
antagonists are capable of attenuating psychostimulant-
induced sensitization,hyperactivity,and hedonic behav-
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Figure 2. Thymoleptic agents, which exert major effects on the glutamatergic system. The various glutamate receptors and the presumed antiglu-
tamatergic drug sites of action are presented. Memantine is a noncompetitive antagonist at the N-methyl-D-aspartate (NMDA) receptor.
Felbamate is a noncompetitive NMDA receptor antagonist (glycine NR1 and glutamate NR2B), an α-amino-3-hydroxy-5-methyl-4-isoxa-
zole propionic acid (AMPA) receptor antagonist, an mGlu group I receptor (mGluRI) antagonist, and a glutamate release inhibitor. Riluzole
is a glutamate release inhibitor (acting through blockade of Na
+ voltage dependent channels), a γ-aminobutyric acid GABAA agonist,
and probably an AMPA and kainate (KA) antagonist. The sites for second-generation mGlu group II and III receptor agonists are also
depicted. NMDAR, NMDA receptor; AMPAR, AMPA receptor; KAR, KA receptor; glu, glutamate; gln, glutamine; mGluRII (or mGluRIII),
mGlu group II (or III) receptor; EAAT, excitatory amino acid transporter; TCA, tricarboxylic acid cycle.
Modified and reproduced with permission from reference 28: Zarate CA, Quiroz J, Payne J, Manji HK. Modulators of the glutamatergic system: implications
for the development of improved therapeutics in mood disorders. Psychopharmacol Bull. 2002;36:35-83. Copyright © 2002. MedWorks Media LLC. 
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70-75 provides compelling behavioral support for our
contention that AMPA receptors play important roles in
regulating affective behavior.
As mentioned already,in striking contrast to the effects
seen with the antimanic agents lithium and valproate,we
found that the chronic administration of the antidepres-
sant imipramine—which is capable of triggering manic
episodes in susceptible individuals
78—increased hip-
pocampal synaptic expression of GluR1.Very recent stud-
ies from other laboratories have also demonstrated that
chronic administration of antidepressants enhances mem-
brane expression of GluR1 as well as phosphorylation of
GluR1 at the PKA site (p845) and the CAMKII/PKC site
(p831).
79,80 Furthermore, it is noteworthy that AMPA
potentiating agents reportedly have efficacy in preclinical
models of depression.
81Additionally,chronic exposure to
the psychostimulants amphetamine and cocaine caused
an increase in GluR1 level in the ventral tegmental area
(VTA),and these effects have been postulated to repre-
sent a trigger for sensitization to drug abuse.
82An elegant
series of studies has recently provided insights into how
dopamine receptors,which are activated during psycho-
stimulant administration, might influence glutamate-
dependent forms of synaptic plasticity,which are being
increasingly recognized as important to drug addiction.
83
They showed that surface GluR1 labeling on processes of
medium spiny neurons and interneurons was increased
by brief incubation with a dopamine D1 agonist.
83
Although these studies were designed to investigate the
role of GluR1 in mediating the effects of drugs of abuse,
it is noteworthy that many of the symptoms of mania
resemble the effects of psychostimulants (eg,locomotor
hyperactivity, racing thoughts, reduced sleep, and psy-
chosis).Taken together,the biochemical and behavioral
studies investigating the effects of antimanic (lithium and
valproate) and promanic (antidepressants,cocaine,and
amphetamine) agents on GluR1 strongly suggest that
AMPA receptor trafficking is an important target in the
pathogenesis and treatment of certain facets of bipolar
disorder.The mechanisms by which glutamate receptors
are actively recruited to synapses have long intrigued the
neuroscience community;the information reviewed here
suggests that they may also play important roles in the
pathophysiology and treatment of complex neuropsychi-
atric disorders.
Concluding remarks
Regionally selective impairments of structural plasticity
and cellular resiliency, which have been postulated to
contribute to the development of classical neurodegen-
erative disorders, may also exist in mood disorders. It
remains unclear whether these impairments correlate
with the magnitude or duration of the biochemical per-
turbations in mood disorders, reflect an enhanced vul-
nerability to the deleterious effects of these perturba-
tions (eg,due to genetic factors and/or early life events),
or indeed represent the fundamental etiological process
in mood disorders. Nevertheless, it is noteworthy that
there is growing evidence from preclinical and clinical
research that the glutamatergic system is involved in the
pathophysiology and treatment of mood disorders.
Over the last few years, an impressive amount of infor-
mation has been gathered regarding the mechanisms
underlying the regulation of AMPA receptor localiza-
tion at synapses.The findings that mood stabilizers—in
therapeutically meaningful paradigms—regulate AMPA
receptors at synapses opens new potential avenues for
new drug development in regards to regulating gluta-
matergic synaptic strength in critical neuronal circuits
(Figure 2). The development of new modulators of
AMPA receptor signaling for the treatment of mood dis-
orders may lead to improved therapeutics for these dev-
astating disorders. ❏
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Regulación de la plasticidad celular y de la
resiliencia mediante estabilizadores del ánimo:
el papel del tráfico del receptor AMPA
Diversas fuentes aportan una evidencia creciente
acerca de la asociación entre los trastornos del
ánimo severos y reducciones regionales del volu-
men cerebral, como también del número, tamaño
y densidad de la glía y de las neuronas en distintas
áreas cerebrales. Aunque la fisiopatología especí-
fica que está a la base de estos cambios morfomé-
tricos no está totalmente aclarada, los datos sugie-
ren que los trastornos del ánimo severos están
asociados con un deterioro en la plasticidad estruc-
tural y en la resiliencia celular. En este contexto es
destacable que una información creciente sugiere
que el sistema glutamatérgico (que se sabe que
juega un papel importante en la plasticidad neuro-
nal y en la resiliencia celular) puede estar involu-
crado en la fisiopatología y en el tratamiento de los
trastornos del ánimo. El tráfico de la subunidad
GluR1 del receptor AMPA (ácido-3-hidroxi-5-metil-
4-isoxazol propiónico) juega un papel decisivo en la
regulación de varias formas de plasticidad neural.
Es de destacar que estudios recientes han mostrado
que estabilizadores del ánimo, estructuralmente
disímiles, como el litio y el valproato regulan el trá-
fico de la subunidad GluR1 y su localización en las
sinapsis. Estos estudios sugieren que la regulación
de la plasticidad sináptica mediada por el sistema
glutamatérgico puede jugar un papel en el trata-
miento de los trastornos del ánimo y se aumenta la
posibilidad que agentes que afecten más directa-
mente la subunidad GluR1 sináptica se transformen
en nuevas terapias para estas devastadoras enfer-
medades.
Régulation de la plasticité et de la résilience
cellulaires par les stabilisateurs de l’humeur :
le rôle du trafic neuronal du récepteur AMPA 
Il existe de plus en plus d’arguments provenant de
sources différentes en faveur de l’association des
troubles de l’humeur sévères avec des réductions
régionales du volume cérébral, ainsi qu’avec des
réductions en nombre, taille et densité de la glie et
des neurones dans des zones cérébrales discrètes.
Bien que la physiopathologie exacte sous-tendant
ces modifications morphométriques soit incomplè-
tement élucidée, les données suggèrent que les
troubles de l’humeur sévères sont associés à des
déficits de la plasticité structurale et de la résilience
cellulaire. Dans ce contexte il faut remarquer qu’un
nombre croissant de données est en faveur d’une
intervention du système glutamatergique (connu
pour jouer un rôle majeur dans la plasticité neuro-
nale et la résilience cellulaire) dans la physiopatho-
logie et le traitement des troubles de l’humeur. Le
trafic neuronal de la sous-unité GluR1 du récepteur
AMPA (acide glutamate α-amino-3-hydroxy-5-
méthyl-4-isoxazole propionique) et les change-
ments morphologiques qui en résultent jouent un
rôle crucial dans la régulation des différentes
formes de plasticité neuronale. À ce titre il faut
également noter que de récentes études ont mon-
tré que des stabilisateurs de l’humeur structurelle-
ment différents comme le lithium et le valproate
régulent le trafic neuronal des sous-unités GluR1 et
leur localisation dans les synapses. Ces études sug-
gèrent que la régulation de la plasticité synaptique
médiée par le glutamate peut jouer un rôle dans le
traitement des troubles de l’humeur et évoquent la
possibilité pour ces maladies invalidantes d’un nou-
veau traitement par l’intermédiaire de molécules
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